News

Sydney Wess 3/16/26 Sydney Wess 3/16/26

THIS IS IT NETWORK™ Presents WELEAD Women in Leadership Powered by Zoom at SXSW

Sydney Wess 3/16/26 Sydney Wess 3/16/26

Lucia Gaitan, M.D., FACOG, First in Miami to Offer Cerene®Endometrial Cryotherapy for Women with Heavy Periods

Sydney Wess 11/20/25 Sydney Wess 11/20/25

Channel Medsystems Appoints Robert Brown, MBA, CPA, as Chief Financial Officer

Sydney Wess 11/19/25 Sydney Wess 11/19/25

Health Innovation Matters Podcast: Changing the State of Women’s Health Technology and Product Development with Tara Murphy, Channel Medsystems Vice President of Marketing

Important Safety Information

Cerene® Cryotherapy Device is indicated to ablate the endometrial lining of the uterus in premenopausal women with heavy menstrual bleeding due to benign causes for whom childbearing is complete. Pregnancy following the Cerene procedure can be dangerous; therefore, contraception must be used until menopause. The Cerene procedure is not for those who have or suspect uterine cancer; have an active genital, urinary or pelvic infection; or an IUD. There are risks and considerations associated with the use of the Cerene Cryotherapy Device. Temporary side effects may include uterine cramping, vaginal infection, and lightheadedness. For detailed benefit and risk information, consult the Cerene Instructions for Use (IFU) or your healthcare professional. CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician trained in the use of the Cerene Cryotherapy Device. Learn More
CC-26-0306

Patients
Healthcare Professionals
Company
News

Resources

Contact Us
S afety Information

Copyright 2026 Channel Medsystems Inc.